Adults with focal onset seizures experienced significant reductions in their seizure frequency with azetukalner, according to ...

Late-onset epilepsy (LOE) may represent a distinctive neurodegenerative-linked epilepsy subtype, with new data showing that individuals who develop epilepsy after midlife have substantially greater ...

In a phase 3 trial, the agent reduces seizure frequency by up to 53% in treatment-resistant focal epilepsy, with rapid onset ...

Adjunctive azetukalner cut monthly focal onset seizure frequency by 53% in phase III study ...

Epilepsy is best known for seizures, but many people with the condition also experience much more frequent and subtler disruptions.

Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over ...

--Rapport Therapeutics, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric ...

Xenon Pharmaceuticals released positive topline results from a phase three study of its azetukalner drug for focal onset seizures. The study met its primary endpoint for median percent change in ...

Semaglutide initiation is associated with a lower risk for adult-onset epilepsy or seizures in patients with T2DM, according ...

SK Life Science is encouraging patients beetling down the long and winding road toward seizure-free life to switch gears. In a new nationwide direct-to-consumer (DTC) ad, the Xcopri manufacturer asks ...